Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Desmoid tumors
Economic burden and healthcare resource utilization
17 evidence topics · 14 sources
Direct and indirect costs: systematic literature review
“No studies evaluating direct or indirect costs of patients with DT were identified in the literature.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No monetary costs from loss of employment and hospital travel expenses were reported in these studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Danish registry healthcare resource utilization and medication use, 2009 to 2018
“Using Danish health registers, we studied DT patients treated at two sarcoma centers between 2009 and 2018. For each patient, ten persons from the general population were randomly matched on birth year, sex, and region of residence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 56% of DT patients used chemotherapeutic agents, tyrosine kinase inhibitors, NSAIDs, opioids, antidepressants, or steroids at some point during the three years before their DT diagnoses. In contrast, 70% of surgically treated and 63% of non-surgically treated patients used one of these drugs in the subsequent three years, including NSAIDs (45% surgical vs. 33% non-surgical), opioids (39% surgical vs. 27% non-surgical), and steroids (22% surgical vs. 18% non-surgical). The average number of inpatient and outpatient visits, days of hospitalization, and additional surgical procedures were higher among DT patients than the comparison cohort.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Danish registry visits and hospital days within 3 years of diagnosis
“Healthcare resource utilization of patients with DT was substantially higher than that in the comparison cohort, both 1 and 3 years after the diagnosis. Within 3 years after the index date, patients with DT had, on average, 1 inpatient and 7.1 outpatient visits as well as 7.5 days in the hospital compared with an average of 0.8 inpatient and 0.1 outpatient visits and 0.8 days in the hospital in the comparison cohort. The median duration of hospitalization for DT-related surgery was 5 days (interquartile range, 3–7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States academic center resource utilization, 2011 to 2023
“A retrospective cohort study was conducted at the University of Utah Health network. Eligible patients were diagnosed with DTs between January 1, 2011, and July 31, 2023, were ≥18 years old at diagnosis, and had ≥2 DT-related encounters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Healthcare resource utilization was quantified using administrative claims.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“88.5% of patients had at least one outpatient visit related to DTs, with an average number of 2.4 visits per patient per year. In contrast, only a small proportion of patients had emergency visits related to DTs (n = 5, 3.4%). Approximately one fifths of patients (n = 30, 20.3%) required hospitalizations related to DTs with a median length of stay per year of 4.5 days (IQR: 3–8, range: 1–35).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although there was no increase in the proportion of patients who engaged outpatient services, the median number of outpatient visits almost tripled in the event of symptomatic disease (7.2 per patient per year) and doubled during active disease (4.7 per patient per year).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Healthcare use by physical symptom burden in the United Kingdom and the Netherlands
“DTF patients with high symptom burden had clinically relevant lower HRQoL scores compared to patients with low and intermediate symptom burden (p < 0.001) and reported more general and DTF‐related visits to their general practitioner compared to the low symptom burden cluster (p < 0.01). In the multivariate analyses, symptom burden was independently associated with both HRQoL and healthcare utilisation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“DTF patients in the intermediate symptom burden–high pain and high symptom burden clusters were more frequently receiving additional care, mostly from a physiotherapist or psychologist (Table S4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medications for symptom management in the Desmoid Tumor Research Foundation natural history study
Monitoring frequency in the Desmoid Tumor Research Foundation natural history study
“As expected, a higher proportion of participants (77%, 181/235) with a current DT were monitored (regular clinic visits and radiologic assessment, including computed tomography and magnetic resonance imaging) at least every 6 months relative to those without (54%, 49/91).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Work loss attributed to pain: SOS Desmoid survey as summarized in a systematic review
“Studies [4, 41] assessing the impact of DT on employment and job productivity have reported that patients experience a negative impact on their employment due to their disease and find it frustrating being unable to work (26% stopped working and 10% worked part- time; see Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pain-related work disturbances included 17 patients (26%) who stopped working altogether and 7 (10%) who worked only part time due to pain” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Employment and financial difficulty at a United Kingdom sarcoma unit
“DF patients experienced changes to their employment due to their disease and found it frustrating being unable to work and wanting to feel ‘normal’. Some patients felt discriminated due to enforced sick leave, which was demoralising and led to loss of progression within their job role. In addition, financial difficulty resulting from loss of employment and hospital travel expenses was a significant concern for several patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Interruption of work after treatment: Dutch focus groups
“Participants reported that DTF had influenced their working life, as they had to stop working temporarily after treatment. This period ranges from a couple of weeks to two years and in one case not being able to work at all.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden of surgery: literature review
“Since economic data related to DT surgery is lacking, reviews of surgery costs in soft-tissue sarcomas and of general costs of amputations were conducted.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tumors in the extremities have the highest risk of recurrence (30%-90%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although effective in specific cases, surgery may be associated with poor long-term functional outcomes and higher economic costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost of 10-year active surveillance in NHS Scotland
“To estimate the direct costs associated with active surveillance (AS), we adopted a conservative costing approach based on current NHS tariffs, focusing on imaging and clinic visit expenses. The study assumes a 10-year follow-up period. The current cost per MRI was £130. Based on current NHS tariffs, each appointment costs approximately £233.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At a cost of roughly £130 per MRI scan, this translates to a total imaging cost of £2340 per patient. Assuming an equal number of clinic visits throughout the follow-up period, with each consultant-led clinic appointment costing £233 as per current NHS Scotland figures, the total combined cost of imaging and appointments exceeds £6500 per patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost per outcome of sorafenib at Medicare Part D rates
“Current Medicare Part D rates for sorafenib were utilized (dose 400 mg/day, cost $309/day).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At one year, sorafenib was associated with a 43% absolute risk reduction (ARR) of CAR progression and number-needed-to-treat (NNT) of 2.3 patients/year, costing $259,406. At two years, ARR was 48% and NNT of 2.1 patients/year, costing $473,697. When evaluating only patients with RECIST defined radiologic progression, sorafenib patients experienced ARR of 13.9% with NNT 7.2 and estimated costs of $812,052 at one year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote